| Literature DB >> 12812525 |
Paula Tavrow1, Jennifer Shabahang, Sammy Makama.
Abstract
BACKGROUND: Private outlets are the main suppliers of uncomplicated malaria treatment in Africa. However, they are so numerous that they are difficult for governments to influence and regulate. This study's objective was to evaluate a low-cost outreach education (vendor-to-vendor) programme to improve the private sector's compliance with malaria guidelines in Bungoma district, Kenya. The cornerstone of the programme was the district's training of 73 wholesalers who were equipped with customized job aids for distribution to small retailers.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12812525 PMCID: PMC161786 DOI: 10.1186/1475-2875-2-10
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Profile of respondents and outlets (in %, unless noted)
| Female | 56.4 | 55.0 | 55.6 | ||
| Male | 43.6 | 45.0 | 44.4 | ||
| Standard 8 or less | 21.0 | 26.7 | 24.4 | ||
| Form 1–4 | 69.0 | 61.0 | 64.2 | ||
| Above Form 4 | 10.0 | 12.3 | 11.4 | ||
| Owner | 44.6 | 39.7 | 41.7 | ||
| Employee | 28.7 | 19.2 | 23.0 | ||
| Family member | 26.7 | 41.1 | 35.3 | ||
| Rural | 58.4 | 57.6 | 57.9 | ||
| Urban | 41.6 | 42.4 | 42.1 | ||
| Shop/Kiosk | 67.3 | 78.8 | 74.2 | ||
| Pharmacy | 26.7 | 12.6 | 18.3 | ||
| Clinic | 5.9 | 8.6 | 7.5 | ||
| Wholesale pharmarcy | 46.5 | 31.8 | 37.7 | ||
| Wholesale general shop | 33.7 | 52.3 | 44.8 | ||
| Mobile vendor | 31.7 | 11.9 | 19.8 | ||
| Reported average number of malaria clients per day | 10 | 8 | 9 |
*From Pearson chi-square
Percent of outlets having various anti-malarial drugs in stock, by programme status and type of outlet
| CQ | 22.1 | 42.0 | 34.8 | ||
| Informed = 68 | SP | 47.1 | 6.7 | 21.4 | |
| Control = 119 | AQ | 76.5 | 79.0 | 78.1 | |
| CQ | 70.4 | 63.2 | 67.4 | ||
| Informed = 27 | SP | 92.6 | 94.7 | .93.5 | |
| Control = 19 | AQ | 92.6 | 94.7 | 93.5 | |
| CQ | 0.0 | 53.8 | 36.8 | ||
| Informed = 6 | SP | 100.0 | 69.2 | 78.9 | |
| Control = 13 | AQ | 83.3 | 69.2 | 73.7 | |
| CQ | 33.7 | 45.7 | 40.9 | ||
| Informed = 101 | SP | 62.4 | 23.2 | 38.9 | |
| Control = 151 | AQ | 81.2 | 80.1 | 80.6 |
Notes: CQ = chloroquine (to be sold by prescription only); SP = sulfadoxine-pyrimethamine (first-line drug); AQ = amodiaquine (second-line drug); *From Pearson chi-square.
Drugs sold to mystery shoppers and whether told the correct dose
| 180 | (35.7) | 46 | (25.5) | |
| 75 | (14.9) | 5 | (6.6) | |
| 74 | (14.7) | 56 | (75.7) | |
| 30 | (6.0) | 3 | (10.0) | |
| 145 | (28.8) | -- | -- | |
| 504 | (100.0) | 110 | (30.6) | |
Notes: AQ = amodiaquine (second-line drug); SP = sulfadoxine-pyrimethamine (first-line drug); CQ = chloroquine (to be sold by prescription only). *Three were sold anti-malarials (e.g. quinine). Others were sold anti-biotics or anti-pyretics.
Malaria knowledge score* (and standard deviation) by programme status and type of outlet
| Informed outlets (n = 101) | Control outlets (n = 151) | All outlets (n = 252) | p-value** | |
| Shop/Kiosk | 8.8 | 7.0 | 7.7 | .000 |
| (1.6) | (1.6) | (1.9) | ||
| Pharmacy/Chemist | 8.6 | 7.5 | 8.2 | .000 |
| (1.1) | (1.5) | (1.4) | ||
| Clinic | 7.8 | 7.6 | 7.7 | .685 |
| (1.6) | (1.4) | (1.5) | ||
| Total | 8.7 | 7.1 | 7.6 | .000 |
| (1.5) | (1.6) | (1.8) |
*The score was based on a 10-question true/false quiz administered to each outlet, with 10 as maximum score. The questions focused malaria treatment practices, such as whether sulfadoxine-pyrimethamine (SP) is more effective than chloroquine, whether SP is too strong for children, whether SP is a single-dose treatment, etc. **From ANOVA F-test.
Drugs sold to mystery shoppers, by programme status and type of outlet (in %)
| Informed outlets | Control outlets | All outlets | ||
| .000 | ||||
| SP | 31.6 | 2.5 | 13.1 | |
| AQ | 28.7 | 33.2 | 31.6 | |
| CQ | 5.1 | 18.9 | 13.9 | |
| Other anti-malarial | 0.0 | 0.4 | 0.3 | |
| Not an anti-malarial | 5.9 | 6.7 | 6.4 | |
| Not sold any drug | 28.7 | 38.2 | 34.8 | |
| .352 | ||||
| SP | 24.1 | 23.7 | 23.9 | |
| AQ | 48.1 | 63.2 | 54.3 | |
| CQ | 20.4 | 10.5 | 16.3 | |
| Other anti-malarial | 0.0 | 0.0 | 0.0 | |
| Not an anti-malarial | 5.6 | 0.0 | 3.3 | |
| Not sold any drug | 1.9 | 2.6 | 2.2 | |
| .369 | ||||
| SP | 16.7 | 3.8 | 7.9 | |
| AQ | 33.3 | 30.8 | 31.6 | |
| CQ | 8.3 | 26.9 | 21.1 | |
| Other anti-malarial | 0.0 | 7.7 | 5.3 | |
| Not an anti-malarial | 0.0 | 0.0 | 0.0 | |
| Not sold any drug | 41.7 | 30.8 | 34.2 | |
| .000 | ||||
| SP | 28.7 | 5.3 | 14.7 | |
| AQ | 34.2 | 36.8 | 35.7 | |
| CQ | 9.4 | 18.5 | 14.9 | |
| Other anti-malarial | 0.0 | 1.0 | 0.6 | |
| Not an anti-malarial | 5.4 | 5.3 | 5.3 | |
| Not sold any drug | 22.3 | 33.1 | 28.8 | |
Notes: SP = sulfadoxine-pyrimethamine (recommended first-line drug); Amodiaquine (second-line drug only); Chloroquine (not recommended, to be sold by prescription only); Other anti-malarial (quinine, etc.); Not an anti-malarial (anti-pyretics or anti-biotics only). *Based on Pearson chi-square.